BioForce Nanosciences Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $102,411, a significant improvement compared to a net loss of $934,650 in the same period of 2025. The company did not generate any revenue during the quarter, consistent with the previous year, and reported zero sales of its BioForce Eclipse vitamin supplements. Operating expenses decreased to $117,733 from $133,457 year-over-year, primarily due to reduced general and administrative costs.
As of March 31, 2026, BioForce's total assets were $6,347, a slight increase from $786 in the prior year. However, the company faced total liabilities of $727,301, up from $619,329 in 2025, largely due to increased accounts payable and accrued expenses. The accumulated deficit also grew to $162,514,528, reflecting ongoing financial challenges. The company’s cash position at the end of the quarter was $6,347, down from $13,799 a year earlier, indicating a need for additional capital to sustain operations.
In terms of operational developments, BioForce has not reported any significant changes in customer counts or product adoption rates, as it continues to seek market penetration for its nutritional supplements. The company is focusing on expanding its marketing efforts, including a direct marketing and B2B sales campaign, to enhance brand awareness and drive sales. BioForce aims to establish vendor relationships with health food and sporting goods stores, as well as expand its online presence.
The company’s management has acknowledged the need for additional financing to support its business plan and operations. The recent legal settlement of $15,322 provided some relief, allowing the company to cover its expenses temporarily. However, management has expressed concerns about the company's ability to continue as a going concern without further capital infusion. The company is actively exploring opportunities to raise funds and implement its marketing strategy to generate revenue.
Looking ahead, BioForce Nanosciences Holdings, Inc. remains focused on its mission to become a leading provider of nutritional supplements. The company is working to refine its business model and expand its product offerings while navigating the challenges of a competitive market. Management's outlook emphasizes the importance of securing additional funding and successfully executing its marketing initiatives to achieve growth and profitability in the future.
About BIOFORCE NANOSCIENCES HOLDINGS, INC.
BioForce Nanosciences Holdings, Inc. operates in the nutritional supplements industry, focusing on natural vitamins, minerals, powders, and beverages designed to support healthier lifestyles for active individuals across all ages. Its core product, BioForce Eclipse, is a private-label multivitamin and mineral powder marketed through distributors, retailers, and online channels. The company leverages contract manufacturing and private labeling to deliver quality supplements targeting athletes, health-conscious consumers, and the elderly in the U.S. market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.